FDA Launches One-Day Inspectional Assessments Pilot
The U.S. Food and Drug Administration (FDA) has announced a pilot program introducing one-day inspectional assessments as part of a broader initiative to improve the efficiency and targeting of its inspection activities.
According to the FDA, the pilot launched in April 2026 and includes shorter, focused screening assessments designed to complement standard FDA inspections.
The agency stated that the initiative is being conducted across multiple FDA inspectorates, including:
Human and animal foods
Biologics
Medical products
Clinical research programs
FDA Commissioner Marty Makary said the shorter assessments are intended to allow the agency to conduct broader surveillance coverage while minimizing operational disruption, particularly for lower-risk establishments.
Risk-Based Facility Selection
The FDA confirmed that facilities participating in the pilot are selected using risk-based criteria, including:
Product type
Prior inspection outcomes
Operational characteristics
The agency also stated that data gathered during the assessments may support the development of more robust risk models across FDA programs.
According to the announcement, the FDA may use information collected during the pilot to identify:
Recurring compliance themes
Facility-specific risk scores
Discrepancies between registered and actual operations
Approximately 46 Assessments Completed
As of late April 2026, the FDA reported that approximately 46 one-day assessments had been completed.
The agency stated that most assessments resulted in “No Action Indicated” (NAI) outcomes.
The FDA also noted that some assessments extended beyond one day when significant observations were identified.
Assessments Will Not Replace Standard Inspections
The FDA emphasized that one-day inspectional assessments are not intended to replace standard FDA inspections.
According to the agency, investigators retain the authority to expand the scope or duration of an assessment if necessary.
The FDA also clarified that:
The pilot does not represent a change in enforcement policy
The approach does not apply to higher-risk or more complex facilities requiring comprehensive inspection coverage
FDA Associate Commissioner for Inspections and Investigations Elizabeth Miller stated that the agency is analyzing operational and compliance data from the pilot, including trends in outcomes, risk signals, and investigator feedback.
Pilot Continues Through Fiscal Year 2026
The FDA confirmed that the pilot will continue through fiscal year 2026, with additional assessments planned across inspectorates.
The agency stated that it is developing evaluation metrics to assess the effectiveness of the initiative, including:
Inspection duration
Escalation rates
Utility of findings in risk-based decision-making
Read the full document below.
